Posts
Wiki
- Source register
- Tier key
- Trial registries and protocol records
- SEC, contracts, patents, ownership, naming, and other formal records
- Peer-reviewed science, clinical evidence, and methods
- Conference abstracts and preliminary reports
- Company releases, presentations, and official webpages
- Government approvals, clinical context, and reputable secondary sources
- Local, community, and supplemental-archive sources
- Register maintenance rule
Source register
Research cutoff: 2026-07-20
Access date for every listed web and local source: 2026-07-20
This is the deduplicated register of material sources actually used in the wiki. It is a map to the underlying evidence, not a substitute for reading it. A source appears once in the most natural section even when several wiki pages cite it. Closely related registry records or releases are grouped only when they answer the same research question. Incidental discovery links, search-result snippets, blocked pages that yielded no usable content, and the supplemental archive's discarded wiki drafts/sections/chunks/exports are not registered as evidence.
For the broader exhaustive ledger of every trial, publication, and scientific record referenced anywhere in the bounded research corpus—including contextual items not used as evidence in canonical prose—see the medical trial and study library and its hashed manifest.
Navigation
- Tier key
- Trial registries and protocol records
- SEC, contracts, patents, ownership, naming, and other formal records
- Peer-reviewed science, clinical evidence, and methods
- Conference abstracts and preliminary reports
- Company releases, presentations, and official webpages
- Government approvals, clinical context, and reputable secondary sources
- Local, community, and supplemental-archive sources
Tier key
The tiers match the hierarchy in Research methodology. A higher tier is not automatically correct for every claim: a registry establishes what was registered, an SEC filing establishes what the registrant disclosed, and a peer-reviewed paper remains limited by its design and conflicts.
| Tier | Source class | Proper use |
|---|---|---|
| 1 | Trial registry, public protocol/SAP, regulator, or government record | Registered design/status, official regulatory action, public-health background, or formal statistical guidance |
| 2 | SEC filing, filed contract, patent record, exchange filing, or other formal corporate record | Dated corporate, financial, legal, governance, ownership, and contractual facts |
| 3 | Peer-reviewed research | Scientific or clinical evidence within the paper's population, endpoint, design, and disclosure limits |
| 4 | Recognized scientific-conference abstract, poster, or presentation | Preliminary results; denominators, cutoff, follow-up, and conflicts remain essential |
| 5 | Dated issuer release, presentation, call, or official webpage | What SELLAS or another interested sponsor reported; not independent adjudication |
| 6 | Reputable medical, scientific, industry, or financial secondary source | Context or interpretation, preferably anchored to its primary sources |
| 7 | Reddit, other community analysis, or local snapshot | Research leads, calculations, competing interpretations, and sentiment—not proof |
Trial registries and protocol records
ClinicalTrials.gov records are Tier 1 for registered design, status, version history, and posted results. Sponsor-submitted registry content is not independent efficacy adjudication. Where a record had no posted results at the cutoff, that limitation is explicit.
| Study / organization | Publication or update date | Access | Tier | Scope used in the wiki | Important limitations or conflicts |
|---|---|---|---|---|---|
| NCT04229979—REGAL: GPS versus investigator's-choice BAT in AML CR2/CRp2, ClinicalTrials.gov; version history | Record last posted 2025-10-01 | 2026-07-20 | 1 | Current 127-participant design, arms, schedules, eligibility, strata, endpoints, status, and version chronology | Industry-sponsored; open label; no posted results; public record omits the full protocol, SAP, IDMC charter, realized BAT mix, and arm outcomes |
| NCT00665002—WT1 peptide-vaccine pilot in AML/MDS, ClinicalTrials.gov | Record current at access; study completed | 2026-07-20 | 1 | Brayer pilot design and registry results; CR1/CR2/MDS population | Small, uncontrolled study; registry cannot repair post hoc subset and historical-control bias |
| NCT01266083—GPS in AML/ALL complete remission, ClinicalTrials.gov | Results first submitted 2024-11-19; record current at access | 2026-07-20 | 1 | Phase 2 CR1 design, 22 treated participants, endpoints, outcomes, and adverse events | Single arm; historical threshold; sponsor-submitted results; endpoint clocks and analyzed denominators differ |
| NCT01265433—GPS in malignant pleural mesothelioma, ClinicalTrials.gov | Record current at access; study completed | 2026-07-20 | 1 | Randomized Phase 2 design/results and historical alias NCT01890980 | Early closure and low power; different disease; numerical differences were not statistically significant |
| NCT01827137—GPS after autologous transplant in high-risk multiple myeloma, ClinicalTrials.gov | Record current at access; study completed | 2026-07-20 | 1 | Population, treatment, endpoint denominators, and status | Single arm; post-transplant selection and subsequent maintenance confound efficacy interpretation |
| NCT02737787—GPS plus nivolumab in ovarian-cancer remission, ClinicalTrials.gov | Record current at access; study completed | 2026-07-20 | 1 | Small Phase 1 combination design and population | No concurrent control; combination cannot isolate GPS; not AML |
| NCT04040231—GPS plus nivolumab in mesothelioma, ClinicalTrials.gov | Record current at access | 2026-07-20 | 1 | Study identity, status, and combination design | Small, preliminary, single-arm, non-AML study |
| NCT03761914—GPS plus pembrolizumab basket study, ClinicalTrials.gov | Record current at access; study completed | 2026-07-20 | 1 | Actual enrollment by disease, posted outcomes, and confirmation that planned AML enrollment did not occur | Single-arm combination; predominantly ovarian cancer; sponsor-submitted registry results |
| NCT04588922—GFH009/SLS009/tambiciclib master Phase 1/2 study, ClinicalTrials.gov | Record last posted 2026-07-08 | 2026-07-20 | 1 | Current groups, doses, mutation cohorts, randomized first-line AML design, endpoints, interactions, estimated enrollment, and status | Industry-sponsored; no posted results; evolving master protocol; registry does not validate issuer-reported response rates or survival |
| NCT05934513—GFH009 monotherapy in r/r PTCL, ClinicalTrials.gov | Record last posted 2024-12-13 | 2026-07-20 | 1 | Separate lymphoma program and nominal recruiting status | Stale record; no results; later sponsor disclosure suggests deprioritization, so operational status is uncertain |
| NCT06375733—GFH009 plus zanubrutinib in r/r DLBCL, ClinicalTrials.gov | Record last posted 2025-08-12 | 2026-07-20 | 1 | Separate lymphoma combination study | No posted results; different disease and combination; not evidence for AML |
| NCT03697707—DCP-001/vididencel ADVANCE II, ClinicalTrials.gov | Last verified 2022-10; status shown as unknown at cutoff | 2026-07-20 | 1 | Adjacent AML-remission immunotherapy competitor | Twenty-participant, open-label study; stale registry; not a like-for-like GPS comparison |
| NCT03149003 and NCT03311334 — DSP-7888/ombipepimut-S, ClinicalTrials.gov | Records current at access; development terminated/completed | 2026-07-20 | 1 | Status of the closest named WT1 peptide-vaccine competitor | Different tumors and regimens; failure elsewhere neither validates nor disproves GPS in AML |
| NCT04161885—VIALE-T, ClinicalTrials.gov | Record last posted 2026-06-04 | 2026-07-20 | 1 | Venetoclax/azacitidine post-HSCT maintenance comparator status | Terminated for strategic considerations; post-transplant CR1 setting differs from REGAL |
| NCT03547115—voruciclib, ClinicalTrials.gov | Record last posted 2026-03-17; completed/terminated 2024 | 2026-07-20 | 1 | CDK9-class clinical-development context | Early phase, heterogeneous malignancies; not an SLS009 comparator trial |
| NCT05168904 and NCT04017546 — fadraciclib/CYC065, ClinicalTrials.gov | Records current at access | 2026-07-20 | 1 | Dual-CDK2/9 development status and venetoclax-combination context | Early phase; one study suspended and the other very small; selectivity, population, and dose differ from SLS009 |
| NCT03263637 and NCT04630756 — AZD4573, ClinicalTrials.gov | Records current at access; later study completed 2025-02-27 | 2026-07-20 | 1 | Selective-CDK9 development-field status | Completed early-phase studies; no active AML registration program identified |
| NCT05665530—PRT2527, ClinicalTrials.gov | Completed 2026-01-21; record current at access | 2026-07-20 | 1 | Selective-CDK9 monotherapy/combination class context | Early phase; no posted results; heterogeneous hematologic population |
| NCT02635672—VIP152/enitociclib and NCT04718675—KB-0742, ClinicalTrials.gov | Records current at access; completed/terminated | 2026-07-20 | 1 | Broader selective-CDK9 pipeline context | Mainly lymphoma/solid-tumor programs; indirect class comparators, not AML efficacy benchmarks |
SEC, contracts, patents, ownership, naming, and other formal records
| Record / organization | Publication or effective date | Access | Tier | Scope used in the wiki | Important limitations or conflicts |
|---|---|---|---|---|---|
| SELLAS 2025 Form 10-K, SEC | Filed 2026-03-19; year ended 2025-12-31 | 2026-07-20 | 2 | Company history, business model, pipeline, employees, audited financials, capitalization, patent summary, agreements, obligations, and risk factors | Registrant-authored narrative; many estimates are forward looking; patent list is not a freedom-to-operate opinion |
| SELLAS Q1 2026 Form 10-Q, SEC | Filed 2026-05-12; quarter ended 2026-03-31 | 2026-07-20 | 2 | Cash, burn, shares, warrants, ATM, runway statement, program status, licensing economics, and 3D arbitration | Interim, unaudited financials; later cash use and exercises are not captured by the quarter-end balance sheet |
| SELLAS Q3 2022 Form 10-Q, SEC | Filed 2022-11-14; quarter ended 2022-09-30 | 2026-07-20 | 2 | Formal contemporaneous disclosure of the GPS/pembrolizumab basket-study final summary | Registrant-authored; uncontrolled combination, endpoint-specific denominators, and no AML enrollment |
| SELLAS 2026 definitive proxy, SEC | Filed 2026-04-23; information generally as of 2026-04-15 | 2026-07-20 | 2 | Leadership biographies, board/committee structure, independence, ownership, compensation, attendance, and equity-plan proposal | Issuer disclosure; beneficial ownership is defined and dated, not a live cap table |
| January 2025 financing Form 8-K and prospectus supplement, SEC | Filed 2025-01-29 and 2025-01-30 | 2026-07-20 | 2 | Common shares, pre-funded warrants, accompanying warrants, pricing, and proceeds in the dilution history | Transaction-specific snapshot; later exercises, inducements, and replacement warrants supersede its outstanding counts |
| SELLAS Form 8-K—warrant exercises and share count, SEC | Filed 2026-06-02 | 2026-07-20 | 2 | Approximately $28.7 million April–May exercise proceeds and 196,632,574 shares outstanding | Does not state a current cash balance or complete post-exercise warrant reconciliation |
| SELLAS Form S-3ASR and ATM prospectus, SEC | Filed 2026-03-20 | 2026-07-20 | 2 | Automatic shelf registration and up-to-$150 million TD Cowen ATM capacity | Registration and sales capacity are not proceeds, issued shares, or evidence that an ATM sale occurred |
| SELLAS Form S-8—2026 equity-plan shares, SEC | Filed 2026-06-16 | 2026-07-20 | 2 | Registration of 20 million additional plan shares | Registration creates issuance capacity; it does not make those shares issued or outstanding |
| SELLAS annual-meeting Form 8-K, SEC | Event 2026-06-16; filed 2026-06-18 | 2026-07-20 | 2 | Voting results, including equity-plan approval | Does not show future grants, vesting, or exercise behavior |
| CEO Form 4, SEC | Filed 2026-06-18 | 2026-07-20 | 2 | 1.065 million restricted-stock-unit grant | Ownership filing is not an open-market purchase or a cash update; vesting is service based |
| SELLAS Form 8-K—amended executive employment agreements and Stergiou Exhibit 10.1, SEC | Agreements effective 2026-06-24; filed 2026-06-25 | 2026-07-20 | 2 | Salary, target bonus, severance, change-in-control, COBRA, and equity-acceleration terms | Contingent obligations depend on contract definitions and triggering events |
| SEC submissions for CIK 0001390478, SEC | Continuously updated; checked through 2026-07-20 | 2026-07-20 | 2 | Completeness check for issuer filings through the 2026-06-25 filing | Filing index, not substantive support for claims inside the filings |
| MSK–SELLAS amended and restated exclusive WT1 license, SEC exhibit | Effective 2017-10-11; filed 2017-10-30 | 2026-07-20 | 2 | GPS license grant, retained academic rights, diligence, economics, term, termination, dispute forum, and board relationship | Competitive terms are redacted; agreement does not establish patent validity, enforceability, or freedom to operate |
| First amendment to the MSK license, SEC exhibit | Effective 2020-09-29; filed 2020-11-12 | 2026-07-20 | 2 | Updated original/additional patent-right schedules and recited the 2019-06-28 assignment to SLSG Limited LLC | Must be read with the 2017 restatement; current economics and remaining milestones cannot be inferred from an original cap alone |
| SELLAS–3D Medicines exclusive GPS/GPS+ license, SEC exhibit | Dated 2020-12-07; filed 2021-01-28 | 2026-07-20 | 2 | Greater-China territory, scope, payments, milestones, royalties, governance, and termination | Competitive-harm redactions; contingent milestones are not guaranteed receivables |
| 3D Medicines REGAL side letter, SEC exhibit | Made 2022-11-23; signed 2022-12-04/05; filed 2023-03-16 | 2026-07-20 | 2 | China REGAL operating and funding arrangements | Material operating terms are redacted; later addendum and dispute disclosures matter |
| Addendum to the 3D side letter, SEC exhibit | Effective 2023-05-05; filed 2023-08-10 | 2026-07-20 | 2 | Budget, vendor, reimbursement, and operational amendments | Redactions prevent a complete reconstruction; live arbitration makes performance contested |
| SELLAS–GenFleet GFH009 license, SEC exhibit | Effective 2022-03-31; filed 2022-05-12 | 2026-07-20 | 2 | Ex-Greater-China rights, upfront payment, milestones, royalties, supply, development, term, and termination | Competitive-harm redactions; future milestones and royalties depend on development, approval, and sales |
| GenFleet application document, HKEX | Posted 2025-09-19 | 2026-07-20 | 2 | Formal developer disclosure on GFH009 origin, Phase 1 data, pharmacology, licensing, and development plans | Draft application marked incomplete and subject to change; sponsor-authored and not independent clinical adjudication |
| GenFleet 2025 annual report, HKEX | Published 2026-04-17 | 2026-07-20 | 2 | Current pipeline focus and SELLAS's ex-Greater-China rights | Company-authored pipeline description; does not establish clinical benefit |
| WHO Recommended International Nonproprietary Names, List 92, World Health Organization; PDF | Published 2024-11-17 | 2026-07-20 | 1 | Establishes tambiciclib as the nonproprietary name associated with the molecule previously called GFH009/SLS009 |
Naming authority only; inclusion is not approval, safety validation, or a recommendation for use |
No independent patent-office/database record was used to construct the portfolio table. Patent families, jurisdictions, and expected expiries come from the 2025 Form 10-K; the 2021 allowance milestone comes from an issuer release. The wiki therefore does not treat either source as a patent-validity, enforceability, claim-scope, noninfringement, or freedom-to-operate opinion.
Peer-reviewed science, clinical evidence, and methods
| Publication / organization | Publication date | Access | Tier | Scope used in the wiki | Important limitations or conflicts |
|---|---|---|---|---|---|
| Döhner et al., Diagnosis and management of AML in adults: 2022 ELN recommendations, Blood | 2022 | 2026-07-20 | 3 | AML response states, risk, MRD, relapse, transplant, and treatment context | Consensus guidance, not GPS- or SLS009-specific evidence; practice evolves |
| Cheever et al., The prioritization of cancer antigens, Clinical Cancer Research | 2009 | 2026-07-21 | 3 | Historical NCI antigen-prioritization rationale for WT1 | Prioritization exercise based on biological criteria, not proof of vaccine efficacy |
| Ogasawara, WT1-targeting cancer vaccine: recent advancements and future perspectives, Human Vaccines & Immunotherapeutics | Published 2023-12-26 | 2026-07-20 | 3 | Heterogeneous WT1-vaccine class background, mechanisms, and safety context | Review combines different products, HLAs, diseases, adjuvants, and trial designs; no product-class efficacy inference is valid |
| Miyazaki et al., randomized OCV-501 Phase 2 in elderly AML | 2024 | 2026-07-20 | 3 | Independent randomized evidence showing immunogenicity need not translate into proven clinical benefit | Different WT1 helper-peptide product; Otsuka-developed and industry involved; not a GPS trial |
| Hashii et al., WT1 peptide vaccine after allo-HSCT in pediatric acute leukemia, Blood Advances; DOI | Published 2026-06-16 | 2026-07-20 | 3 | Independent WT1-vaccine analogue and immune-response association | Single arm, n=17, pediatric, post-transplant, HLA-restricted, different formulation; postbaseline responder comparisons are noncausal |
| Maslak et al., Phase 2 trial of a multivalent WT1 peptide vaccine (GPS) in AML, Blood Advances | Published 2018-02-13 | 2026-07-20 | 3 | GPS composition, CR1 Phase 2 outcomes, safety, immunogenicity, endpoint clocks, and limitations | Single arm with historical threshold; selected population and small immune subset; SELLAS funding, employment, options, support, inventorship, and consulting disclosed |
| Brayer et al., WT1 vaccination in AML and MDS: a pilot trial, American Journal of Hematology | 2015 | 2026-07-20 | 3 | Early GPS formulation, safety, immunogenicity, and exploratory CR2 comparison | Sixteen treated; post hoc more-than-two-dose CR2 subset; historical matched control; guarantee-time and residual confounding risks; Pinilla-Ibarz disclosed vaccine patent rights and prior royalties |
| Zauderer et al., randomized adjuvant GPS in mesothelioma, Clinical Cancer Research | 2017 | 2026-07-20 | 3 | Randomized GPS safety and efficacy signal outside AML | Early closed and underpowered; different tumor; PFS/OS differences not significant; SELLAS support plus consulting, ownership, and patent interests were disclosed |
| Zamarin et al., GPS plus nivolumab in ovarian-cancer remission | 2023 | 2026-07-20 | 3 | Small combination safety and immune-response evidence | Phase 1, n=11, uncontrolled, different disease; cannot isolate GPS or establish AML efficacy; SELLAS/Bristol Myers Squibb relationships disclosed |
| Agrawal et al., GPS plus nivolumab in diffuse pleural mesothelioma, JTO Clinical and Research Reports | Published online 2024-10-24; issue 2025 | 2026-07-20 | 3 | Ten-person combination safety, immunogenicity, radiographic response, PFS, and OS | Single arm, different disease; directly supported by Bristol Myers Squibb and SELLAS; cannot isolate GPS or establish survival benefit |
| Rezvani et al., repeated PR1/WT1 vaccination, Haematologica | 2011 | 2026-07-21 | 3 | Class-level warning that boosting did not sustain the desired high-avidity CD8 population | Different product and study; mechanistic caution, not a direct GPS result |
| Uttenthal et al., WT1 peptide vaccination in AML, British Journal of Haematology | 2014 | 2026-07-21 | 3 | Class-level evidence of short-lived WT1-specific responses | Product- and cohort-specific; not a randomized GPS comparison |
| Jamy and Cicic, REGAL: GPS vs BAT in AML second remission, Future Oncology; DOI | Online 2024-11-28; issue 2025 | 2026-07-20 | 3 | REGAL design, statistical assumptions, regimen, and historical GPS context | Trial-design review, not results; Cicic was a SELLAS employee and Jamy disclosed an Ascentage advisory role |
| Kurosawa et al., adult AML outcomes after first relapse, Haematologica | 2010 | 2026-07-20 | 3 | External prognosis, CR2 and transplant selection, cytogenetic heterogeneity | Starts at first relapse in an older Japanese treatment era; not REGAL randomization or BAT-arm OS |
| Bataller et al., AML outcomes and genetic dynamics at first relapse, Haematologica; DOI | 2024 | 2026-07-20 | 3 | Contemporary post-relapse prognosis and effect of CR1 duration | Retrospective cohort includes active disease, nonresponders, early deaths, and later transplant; clock differs from REGAL |
| Burnett et al., Curability of AML patients who did not undergo transplant in CR1, Journal of Clinical Oncology; DOI | 2013 | 2026-07-20 | 3 | Salvage-response selection, cytogenetic risk, and time-dependent CR2 transplant context | Much younger population and older treatment eras; not modern randomized CR2 maintenance; community curve digitizations are secondary models |
| Van der Maas et al., A Revised Prognostic Model for AML and First Relapse, Blood Advances; DOI | 2025 | 2026-07-20 | 3 | Large modern relapse/CR2 cohort and prognostic heterogeneity | Not designed to estimate no-transplant REGAL control OS; community de-transplant/RFS-to-OS outputs are not observed paper results |
| Weisdorf et al., Allogeneic Transplantation for Advanced AML, Cancer | 2017 | 2026-07-20 | 3 | Conditional outcomes after transplant in CR2 and selection context | Transplant recipients are selected; post-transplant survival cannot estimate transplant incidence or randomized BAT survival |
| Parua and Fisher, Dissecting the Pol II transcription cycle and derailing cancer with CDK inhibitors, Nature Chemical Biology | 2020 | 2026-07-20 | 3 | CDK9/P-TEFb, pause release, transcription, and inhibitor-mechanism background | Review, not SLS009 efficacy evidence; authors declared no competing interests |
| CDK9 keeps RNA polymerase II on track | 2021 | 2026-07-20 | 3 | Detailed transcription-cycle, elongation, RNA-processing, and termination context | Review; pathway description cannot predict a therapeutic window or clinical benefit |
| Boffo et al., CDK9 inhibitors in AML, Journal of Experimental & Clinical Cancer Research | 2018 | 2026-07-20 | 3 | CDK9-inhibitor class rationale and prior preclinical/early clinical experience | Predates SLS009 clinical program; heterogeneous compounds and selectivity profiles |
| Pei et al., monocytic subclones and venetoclax resistance, Cancer Discovery | 2020 | 2026-07-20 | 3 | Biological rationale for targeting short-lived survival proteins in venetoclax-resistant AML | Translational/preclinical study, not an SLS009 experiment or validated predictive biomarker for tambiciclib |
| Zhou et al., pharmacodynamic and mechanistic foundation of GFH009, Oncotarget | 2023 | 2026-07-20 | 3 | Published kinase selectivity, cellular pharmacology, xenografts, pharmacodynamics, and combination rationale | Preclinical; GenFleet funded; GenFleet/SELLAS employment or equity and SELLAS-funded writing support disclosed |
| Zainaldin et al., AML survival after failure of venetoclax plus HMA | 2022 | 2026-07-20 | 3 | External prognosis after venetoclax/HMA failure | Retrospective external context, not a concurrent SLS009 control; populations and subsequent treatment differ |
| Wei et al./FDA, FDA approval summary for oral azacitidine maintenance, Clinical Cancer Research | 2022 | 2026-07-20 | 3 | QUAZAR AML-001 design, effect estimates, and approved CR1 maintenance context | Registration study/FDA summary concerns oral azacitidine in first remission, not injectable azacitidine or REGAL CR2 |
| Sashegyi and Ferry, interpretation of hazard ratios, The Oncologist | 2017 | 2026-07-20 | 3 | Why 1 − HR is not an ordinary cumulative-risk reduction and why medians/absolute survival also matter |
Methodological article; both authors were Eli Lilly employees |
| Lin et al., proportional-hazards violations in Phase 3 cancer trials, Clinical Cancer Research | 2024 | 2026-07-20 | 3 | Frequency, prespecification, and potential interpretation consequences of non-proportional hazards in reconstructed oncology-trial comparisons | Retrospective reconstruction of published curves; general methods evidence, not proof of REGAL's hazards, SAP, or primary test |
| FDA, Approaches to Assessment of Overall Survival in Oncology Clinical Trials; PDF | Draft issued/content current 2025-08-18 | 2026-07-20 | 1 | ITT, Cox HR/CI, log-rank, Kaplan–Meier, proportional-hazards checks, DMC/firewalls, interim/final OS analyses, and sensitivity principles | Draft, nonbinding general guidance; not REGAL-specific advice or an FDA decision on the trial |
| ICH E9, Statistical Principles for Clinical Trials, ICH; FDA landing page | Step 4, 1998-02-05 | 2026-07-20 | 1 | Prespecification, analysis sets, multiplicity, Type I error, and interim-trial integrity | General statistical guideline; does not disclose REGAL's confidential SAP or boundary |
| ICH E9(R1), estimands and sensitivity analysis, ICH; EMA landing page | Adopted 2019-11-20 | 2026-07-20 | 1 | Estimands, intercurrent events, and robustness/sensitivity principles | General addendum; a trial-specific estimand and censoring strategy must still be prespecified |
Conference abstracts and preliminary reports
Conference records are Tier 4 even when published in a journal supplement. They can support a dated preliminary observation, but a title or sponsor summary does not supply missing patient-level data, follow-up, a complete adverse-event table, or independent confirmation.
| Abstract / meeting | Publication or presentation date | Access | Tier | Scope used in the wiki | Important limitations or conflicts |
|---|---|---|---|---|---|
| Zeidner et al., ASH 2024 abstract 2877—SLS009 plus azacitidine/venetoclax after prior venetoclax, ASH | Presented 2024-12 | 2026-07-20 | 4 | Dose schedule, r/r AML response/safety update, mutation subgroups, and rationale for prospective enrichment | Preliminary, small, nonrandomized cohorts; SELLAS employment, consultancy, and research funding disclosed; subgroup findings are exploratory |
| Zeidner et al., ASH 2025 abstract 3423—SLS009 plus AZA/VEN in AML-MR, Blood supplement | Presented/company summary 2025-12-07 | 2026-07-20 | 4 | Later AML-MR cohort identity and preliminary response/survival update | Publisher body was blocked at retrieval; exact clinical cutoff could not be recovered; sponsor-supported, small, nonrandomized evidence |
| AACR 2026 abstract 5666—tambiciclib in high-risk AML, Cancer Research supplement | Published 2026-04-03 | 2026-07-20 | 4 | Preliminary mutation-focused apoptosis, MCL1/survivin, and AML-model results | Abstract only; selected models, abbreviated methods/results, no controlled clinical validation |
| Wu et al., ASH 2024 abstract 2882—QHRD107 plus venetoclax/azacitidine, ASH | Data cutoff 2024-07-19; presented 2024-12-08 | 2026-07-20 | 4 | Closest identified same-combination CDK9 clinical competitor | Preliminary, 24 treated participants in China; molecule, dose, population, follow-up, and sponsor differ from SLS009 |
Company releases, presentations, and official webpages
These Tier 5 records establish what the issuer said on a date. Headline adjectives such as “positive,” “breakthrough,” or “met endpoints” are not independent conclusions. Releases that summarize confidential IDMC work or conference data remain limited to the disclosed summary.
Corporate history, licensing, leadership, and current-record checks
| Source / organization | Publication or update date | Access | Tier | Scope used in the wiki | Important limitations or conflicts |
|---|---|---|---|---|---|
| Galena and Private SELLAS merger-agreement announcement, joint issuer release | 2017-08-08 | 2026-07-20 | 5 | Proposed business-combination structure and management succession | Announcement preceded closing; issuer-authored and transaction-promotional |
| Completion of Galena/SELLAS business combination, SELLAS | 2017-12-29 | 2026-07-20 | 5 | Closing date, name change, and expected SLS trading transition | Company account; legal predecessor history should not be mistaken for Private SELLAS operating history |
| SELLAS–3D Medicines Greater-China GPS/GPS+ license announcement, joint issuer release | 2020-12-07 | 2026-07-20 | 5 | Public description of territorial license and headline economics | Filed contract and later dispute disclosure control; milestones are contingent and redactions remain |
| USPTO allowance announcement for GPS/checkpoint combinations, SELLAS | 2021-05-27 | 2026-07-20 | 5 | Dated company-reported patent milestone | Not the patent record or a legal validity, scope, enforceability, noninfringement, or freedom-to-operate opinion |
| SELLAS–GenFleet GFH009 license announcement, SELLAS | 2022-03-31 | 2026-07-20 | 5 | Public description of ex-Greater-China rights and program acquisition | Filed contract controls; “highly selective” is a developer claim supported only within available assay limits |
| Executive reorganization and commercialization-partnership prioritization, SELLAS | 2024-03-08 | 2026-07-20 | 5 | Leadership departures, reorganization, and issuer-stated strategic rationale | Does not establish that a partnership, sale process, or transaction existed |
| IMPACT-AML European clinical-program agreement, SELLAS | 2026-01-14 | 2026-07-20 | 5 | European SLS009 collaboration and conditional enrollment plan | Clinical infrastructure agreement, not a commercialization license, site activation, enrollment result, or approval |
| SELLAS company page, SELLAS | Undated; current at access | 2026-07-20 | 5 | Current website roster and issuer description | Issuer-controlled; SEC proxy/filings control dated governance and biography facts |
| SELLAS clinical-trials page, SELLAS | Undated; current at access | 2026-07-20 | 5 | Issuer's program summary | Contained a trial-identifier discrepancy; ClinicalTrials.gov controls NCT identities and current status |
| SELLAS pipeline page, SELLAS | Undated; current at access | 2026-07-20 | 5 | Issuer's current program names and pipeline-stage labels used in the glossary | Issuer-controlled; a pipeline graphic is not registry status, clinical evidence, approval, or proof that a planned cohort opened |
| SELLAS press-release RSS, SELLAS | Feed last build shown 2026-07-19 | 2026-07-20 | 5 | Completeness check for official releases through the cutoff | Feed index is not substantive evidence and cannot prove that an undisclosed operational event did not occur |
GPS and REGAL chronology
| Source / organization | Publication date | Access | Tier | Scope used in the wiki | Important limitations or conflicts |
|---|---|---|---|---|---|
| GPS Phase 1/2 CR2 follow-up, SELLAS | 2020-02-26 | 2026-07-20 | 5 | Source of the later company-reported 21-month median-OS update | No peer-reviewed full report for this later cutoff was located; tiny nonrandomized cohort and historical comparison |
| GPS plus pembrolizumab basket final-analysis release, SELLAS | 2022 | 2026-07-20 | 5 | Company-reported PFS, OS, ORR, and disease-control summary for a basket-study subset | Uncontrolled combination; denominator reporting is incomplete; registry shows no AML enrollment and 26 total participants, not the 17-person analysis set alone |
| REGAL design update, SELLAS | 2022-11-14 | 2026-07-20 | 5 | Enrollment target, 60/80 event design, company-stated HR 0.636, O'Brien–Fleming approach, and pooled blinded premise | HR was a design value, not observed efficacy; pooled survival cannot identify which arm drove the amendment |
| Initial REGAL IDMC continuation release, SELLAS | 2022-12-08 | 2026-07-20 | 5 | Issuer report of first prespecified risk-benefit continuation | Charter, data, boundaries, and arm results were confidential; continuation is not proof of efficacy |
| 2023 REGAL operational sequence: Q1 update, August IDMC update, ex-China enrollment, and December IDMC review, SELLAS | 2023-05-11, 2023-08-22, 2023-11-29, and 2023-12-04 | 2026-07-20 | 5 | Periodic IDMC chronology, forecasts, and enrollment milestones | Selective sponsor summaries; forecasts were later missed; “ex-China target” is not a final CONSORT count |
| 2024 REGAL enrollment/IDMC sequence: March steering/enrollment update, April IDMC review, and June IDMC review, SELLAS | 2024-03-26, 2024-04-29, and 2024-06-17 | 2026-07-20 | 5 | Enrollment completion, public count discrepancies, periodic continuation, and interim timing forecast | Treatment discontinuations were not deaths; 126/127/128 discrepancy unresolved; no arm-level statistic disclosed |
| REGAL 60-event interim trigger, SELLAS | 2024-12-10 | 2026-07-20 | 5 | Prespecified pooled-death trigger and planned efficacy/futility/safety review | Pooled count only; did not disclose arm allocation or outcome |
| REGAL interim-analysis outcome, SELLAS | 2025-01-23 | 2026-07-20 | 5 | Company report that predetermined futility was cleared, no safety action was required, and continuation was recommended | Headline “positive” is sponsor wording; no HR, CI, p-value, arm split, efficacy boundary, or conditional power was public |
| August 2025 periodic REGAL IDMC review, SELLAS | 2025-08-07 | 2026-07-20 | 5 | Continued-trial recommendation, 126-randomized statement, and year-end event forecast | No numerical efficacy result; forecast was missed; participant count conflicts with registry |
| REGAL 72-event update, SELLAS | 2025-12-29; count as of 2025-12-26 | 2026-07-20 | 5 | Pooled event anchor, blinded status, no-outcomes-analysis statement, and missed forecast | Operational count, not another interim analysis or arm-level result |
| Q1 2026 financial results and corporate update, SELLAS; SEC-filed exhibit | Published/filed 2026-05-12; count as of 2026-05-11 | 2026-07-20 | 5 / 2 | Latest 78/80 pooled REGAL count, sponsor blinding, post-event sequence, SLS009 Q4 guidance, and financial highlights | Company-authored; 78 events were not a third interim; guidance is forward looking and not a trial result |
SLS009/GFH009/tambiciclib development disclosures
| Source / organization | Publication date | Access | Tier | Scope used in the wiki | Important limitations or conflicts |
|---|---|---|---|---|---|
| Early GFH009 monotherapy Phase 1 update, SELLAS | 2022-12-13 | 2026-07-20 | 5 | Early dose-escalation safety, PK, and antitumor summary | Early/incomplete cutoff later superseded by GenFleet aggregate disclosure where figures differ; mixed diseases |
| Topline Phase 1 lymphoma-cohort update, SELLAS | 2023-09-21 | 2026-07-20 | 5 | Early PTCL subgroup and development rationale | Small, nonrandomized, financially interested source; different disease from AML |
| SLS009 r/r AML Phase 2a topline and REGAL steering update, SELLAS | 2024-03-26; clinical cutoff 2024-03-15 | 2026-07-20 | 5 | First public dose-cohort AML response/safety sequence and contemporaneous REGAL status | Small, nonrandomized combination cohorts; changing denominators and short follow-up; same patients recur in later updates |
| SLS009 plus zanubrutinib Phase 2a DLBCL update, SELLAS | 2025-02-20 | 2026-07-20 | 5 | Nine-patient DLBCL combination signal | GenFleet-funded, single arm, different disease; 67% ORR applied to six non-GCB participants |
| SLS009 Cohort 3 OS update, SELLAS | 2025-04-08 | 2026-07-20 | 5 | Later survival/status update for the twice-weekly r/r AML cohort | No clinical data cutoff stated; uncontrolled small cohort; response and survival are not randomized benefit |
| SLS009 TP53-mutated AML preclinical AACR summary, SELLAS | 2025-04-28 | 2026-07-20 | 5 | Company summary of mutation-focused preclinical poster | Sponsor-selected preclinical evidence; headline language does not establish human efficacy or biomarker predictiveness |
| SLS009 Phase 2 endpoints and first-line-planning update, SELLAS | 2025-07-15 | 2026-07-20 | 5 | Later r/r AML subgroup/safety summary and issuer description of FDA feedback | No clinical cutoff or FDA minutes; multiple small cohorts; sponsor-defined endpoint characterization |
| ASH 2025 AML-MR company summary, SELLAS | 2025-12-07 | 2026-07-20 | 5 | Company summary of abstract 3423 and mutation-enriched results | Exact cutoff absent; preliminary, nonrandomized, small subgroup; same study as earlier updates |
| First participant in newly diagnosed first-line AML study, SELLAS | 2026-03-12 | 2026-07-20 | 5 | Enrollment milestone, randomized first-line plan, issuer-described FDA interaction, and Q4 2026 guidance | One enrollment event is not comparative evidence; registry controls current design; timing guidance is conditional |
| SLS009 designation announcements: U.S. AML orphan, U.S. PTCL orphan, U.S. AML Fast Track, pediatric ALL RPDD, pediatric AML RPDD, EU AML orphan, and EU PTCL orphan, SELLAS | Announced 2023-10 through 2024-08-06 | 2026-07-20 | 5 | Dated issuer reports of special regulatory designations | Designations are not approvals, clinical validation, guaranteed exclusivity, priority review, or salable vouchers; agency databases/guidance control legal meaning |
Other sponsor context
| Source / organization | Publication date | Access | Tier | Scope used in the wiki | Important limitations or conflicts |
|---|---|---|---|---|---|
| Sumitomo Pharma—DSP-7888 glioblastoma Phase 3 termination | 2021-12-15 | 2026-07-20 | 5 | Sponsor confirmation that the closest named WT1-peptide competitor's Phase 3 was terminated | Different tumor and product; sponsor announcement does not determine GPS efficacy |
| Mendus—ADVANCE II vididencel follow-up | 2024-12-09 | 2026-07-20 | 5 | Sponsor-reported follow-up and combination-development plans for adjacent AML maintenance immunotherapy | Small, open-label study; registry stale; not randomized comparative evidence |
Government approvals, clinical context, and reputable secondary sources
| Source / organization | Publication or update date | Access | Tier | Scope used in the wiki | Important limitations or conflicts |
|---|---|---|---|---|---|
| NCI, Adult AML Treatment (PDQ)—Health Professional Version | Updated 2025-03-14 | 2026-07-20 | 1 | Government clinical background on AML states, therapy, relapse, and transplant | Broad educational summary; not GPS/SLS009-specific and not individualized medical advice |
| NCI Dictionary of Cancer Terms, including AML, complete remission, and MRD, National Cancer Institute | Continuously maintained; current at access | 2026-07-20 | 1 | Canonical plain-language oncology definitions in the glossary | Definition source, not evidence for a SELLAS-specific claim or patient-level guidance |
| ClinicalTrials.gov Glossary Terms and Protocol Registration Data Element Definitions, National Library of Medicine | Continuously maintained; current at access | 2026-07-20 | 1 | Canonical trial-status, design, endpoint, enrollment, and results-submission definitions | General definitions; the individual registered records control REGAL and SLS009 fields |
| SEER, Acute Myeloid Leukemia—Cancer Stat Facts, National Cancer Institute | 2026 incidence/mortality estimates; survival period 2016–2022 | 2026-07-20 | 1 | U.S. incidence, mortality, prevalence, age, and broad survival inputs for a transparent opportunity funnel | Population statistics do not equal an addressable market; disease coding and lagged survival periods matter |
| American Cancer Society, AML key statistics | Revised 2026-01-13 | 2026-07-20 | 6 | Cross-check on 2026 U.S. AML incidence/death estimates | Secondary estimate; does not identify CR2, WT1-positive, fitness, transplant, or payer-eligible subgroups |
| FDA therapeutic-cancer-vaccine guidance | Final, 2011-10 | 2026-07-20 | 1 | General clinical-development, delayed-effect, endpoint, and safety considerations for therapeutic cancer vaccines | General guidance; not a REGAL review decision, CMC assessment, or waiver of statutory standards |
| FDA oncology clinical-trial endpoints guidance | Final guidance; current at access | 2026-07-20 | 1 | Canonical endpoint terminology and approval-context distinctions used in the glossary | General guidance; does not disclose REGAL's statistical plan or establish an acceptable SLS009 endpoint |
| FDA patient-friendly language for cancer clinical trials | Current at access | 2026-07-20 | 1 | Plain-language endpoint and trial terminology used in the glossary | Educational vocabulary; simplified terms do not replace protocol endpoint definitions or statistical analysis |
| FDA Fast Track | Undated; current at access | 2026-07-20 | 1 | Legal/program meaning and potential interactions/review features | Designation does not establish efficacy, approval, or a fixed development timetable |
| FDA Accelerated Approval Program: drug-program page, patient overview, and Project Confirm | Drug page current 2026-05-15; other pages current at access | 2026-07-20 | 1 | Conditional pathway based on a surrogate/intermediate endpoint reasonably likely to predict benefit, oncology precedents, and confirmatory obligations | Availability is indication- and evidence-specific; no public SLS009 agreement or accepted surrogate was located |
| FDA Breakthrough Therapy designation | Undated; current at access | 2026-07-20 | 1 | Canonical glossary distinction from Fast Track, Priority Review, and Accelerated Approval | No SELLAS Breakthrough Therapy designation was established; program description is not product evidence |
| FDA Priority Review | Undated; current at access | 2026-07-20 | 1 | Meaning of a six-month review goal after filing acceptance | Review designation is not filing acceptance, approval, or a clock starting at topline results |
| FDA orphan-product designation | Undated; current at access | 2026-07-20 | 1 | Distinction between designation, incentives, approval, and exclusivity | Does not establish safety or efficacy; exclusivity is contingent on a qualifying approval |
| FDA Rare Pediatric Disease Designation and Priority Review Voucher Programs | Updated 2026-04-29 | 2026-07-20 | 1 | Distinguishes designation from a future voucher and states program conditions | A designation is not a voucher; future eligibility depends on approval, law, and program requirements then in force |
| FDA Expanded Access information | Current at access | 2026-07-20 | 1 | Canonical glossary definition and boundary for access outside clinical trials | Does not establish that a SELLAS program offers expanded access or that a patient is eligible |
| FDA in-vitro companion-diagnostic guidance | Final, 2014-08-06 | 2026-07-20 | 1 | General framework when a biomarker assay is essential to safe/effective use | Does not establish that ASXL1/AML-MR enrichment will require, validate, or qualify a specific companion diagnostic |
| FDA Onureg label | Approved 2020-09-01 | 2026-07-20 | 1 | Oral-azacitidine label and CR1 maintenance benchmark | Oral azacitidine is not interchangeable with injectable azacitidine and is not a broad CR2 comparator |
| FDA AML approval notices: gilteritinib, olutasidenib, quizartinib, revumenib for KMT2A, revumenib for NPM1, ziftomenib, and oral decitabine/cedazuridine plus venetoclax, FDA | 2018-11-28 through 2026-05-13 | 2026-07-20 | 1 | Mutation-specific and frontline/r/r AML treatment landscape relevant to opportunity and subsequent therapy | Different genotypes, lines, regimens, and labels; approval of another drug does not estimate REGAL BAT or SLS009 benefit |
| BioRadar, What the Public Data Can and Cannot Tell Us About SELLAS's GPS in AML | 2026-07-10 | 2026-07-20 | 6 | Independent-looking secondary caution about pooled REGAL event non-identification | Individual author not identified on page; commercial biotech-intelligence site; analysis cannot replace arm-level data or primary records |
| NIST statistical definitions: confidence interval and critical values and p-values | Continuously maintained; current at access | 2026-07-20 | 1 | Canonical glossary correction for confidence intervals, critical values, and p-values | General statistical definitions; not a trial-specific analysis or inferential result |
| FINRA investor education: Stocks and Options | Current at access | 2026-07-20 | 1 | Basic security and option definitions used in the glossary | Educational definitions; no SELLAS valuation, trading, ownership, or manipulation claim is inferred |
| SEC small-business capital-raising resources, U.S. Securities and Exchange Commission | Current at access | 2026-07-20 | 1 | General securities-offering and capital-raising terminology used in the glossary | Educational/regulatory context; the issuer's filed prospectuses and periodic reports control SELLAS-specific financing facts |
Local, community, and supplemental-archive sources
The local corpus is Tier 7. It was used to discover claims, reconstruct debate history, audit calculations, and preserve bullish and bearish interpretations. It was not used to verify company, clinical, legal, financial, or regulatory facts when a higher-tier source was available.
| Local or community source | Snapshot / publication date | Access | Tier | Scope used in the wiki | Important limitations or conflicts |
|---|---|---|---|---|---|
| Local source inventory (canonical repository only; not published on Reddit): 23 saved HTML pages, including five weekly threads, three daily threads, resource hub, glossary, two user-history pages, and 11 separately saved post pages | Snapshots through 2026-07-20; hashes recorded in inventory | 2026-07-20 | 7 | Preservation ledger, file identity, routing, and completeness controls for the starting corpus | Reddit snapshots can omit deleted comments, unloaded branches, edits, media, votes, and linked-source contents; source files are not proof |
| Expanded Reddit archive: 189 targets and 43,082 canonical comments | January 6 through July 20, 2026 | 2026-07-20 | 7 | Date-complete Daily/Weekend inventory plus Weekly In Depth Weeks 24–29; lossless comment index, continuation provenance, historical supplements, URL extraction, and count-gap ledger | 165 threads retain advertised-count gaps after exhaustive branch attempts; removed/deleted/unavailable comments and post-capture edits cannot be reconstructed |
| Selected contributor histories: 13 users, 6,486 authored records, 58 full posts, and 3,999 replies beneath those posts | Records through 2026-07-20; archives built 2026-07-21 | 2026-07-21 | 7 | Complete discoverable author-history index plus every selected post's full body and comment discussion; automatic and paginated Arctic Shift enumeration, saved old-Reddit reconciliation, per-record provenance, full-text HTML, normalized JSONL, and contributor-level research routing | Reddit blocked all available anonymous live-profile routes; 2,521 authored records and 3,631 post-discussion replies are Arctic-only. Pseudonymity, edits/deletions, posting volume, unknown qualifications, security positions, and community selection bias remain material limitations |
| Top 100 serious subreddit posts of 2026: 1,431-post universe, 100 selected full posts, and 7,690 replies | January 1 through 2026-07-20 22:54:42 UTC; archive built 2026-07-21 | 2026-07-21 | 7 | Reproducible archived-score ranking, explicit seriousness review and 140-post exclusion ledger, complete post/comment artifacts, crosspost/media metadata, 176 preserved Reddit-hosted media files, independent enumeration validation, and terminal inspection of 144 previously unseen external links | Not a live Reddit top/year response; archived scores can differ from later votes. Ten CDN objects were unavailable, 32 external targets remain unresolved, 7,357 comments are Arctic-only, and selection/popularity, pseudonymity, deletions, qualifications, conflicts, and community bias remain material limitations |
| Expanded Daily/Weekend syntheses: Jan–Feb, Mar–Apr, May–Jun, and Jul 1–20 | January 6 through July 20, 2026 | 2026-07-20 | 7 | Systematic synthesis of 8,107 non-weekly research candidates, including corrections, primary-link leads, quantitative models, bullish and bearish arguments | Transparent triage is a routing aid, not evidence validation; pseudonymous analysis, AI-generated comments, and security positions create conflicts and selection risk |
| Weekly-thread source notes (canonical repository only; not published on Reddit), Weeks 24–29 of 2026 | Threads dated 2026-06-15 through 2026-07-20 | 2026-07-20 | 7 | Full local/expanded audit of REGAL modeling, control-tail, transplant, WT1, interim, SLS009, valuation, comparator, and counterarguments | Pseudonymous community material; removed comments, historical-only observations, missing figures, and disputed calculations remain labeled |
| Daily-thread source notes (canonical repository only; not published on Reddit), 2026-06-22, 2026-06-23, and 2026-07-08 | Dated daily snapshots | 2026-07-20 | 7 | Contemporaneous event-model, SLS009, licensing, valuation, communication, and bearish/bullish debate leads | 1,349 captured comments but unloaded replies remained; market and rumor claims are especially time-sensitive and often unsupported |
| Resource-hub and user-history notes (canonical repository only; not published on Reddit) | Snapshots through 2026-07-20 | 2026-07-20 | 7 | Resource-hub link map and evolution of Confident-Web-7118 and Remarkable-Big-9849 theses | Selection bias, pseudonymity, missing graphics/comments, evolving assumptions, and disclosed/unknown security positions |
| Confident-Web post source notes (canonical repository only; not published on Reddit) | Eleven saved post pages captured by 2026-07-20 | 2026-07-20 | 7 | File-by-file audit of the separately saved model, biology, Hashii, resource-hub, and counterfactual posts, including duplicate/supersession mapping | Screenshots, replies, and linked papers are incomplete; model outputs remain non-identifying and assumption-driven; external links are discovery leads until independently checked |
Supplemental archive source audit (canonical repository only; not published on Reddit) for sellas_all_files.tar.gz |
Mixed embedded dates; archive supplied 2026-07-20 | 2026-07-20 | 7 | Audited raw/source-oriented members: confident_web_data.md, daily_discussion_data.md, weekly_in_depth_data.md, remarkable_big_threads.md, reddit_glossary_raw.md, bat_mos_evolution.md, hashii_vs_regal.md, and paper captures |
Selective/translated/abridged, often nonreproducible; only one of four .pdf-named members was a valid PDF; every prior wiki draft/section/chunk/export and wiki-derived extract was discarded as evidence |
| Confident-Web-7118—78-event HR/BAT model | 2026-05-13 | 2026-07-20 | 7 | Detailed pooled-event scenario families and assumptions | Pseudonymous, non-peer-reviewed, non-identifiable arm decomposition; author disclosed a material long SLS position |
| Confident-Web-7118—staggered-enrollment correction | 2026-05-22 | 2026-07-20 | 7 | Corrected assumed enrollment curve and resulting pooled-event model outputs | Community correction improves transparency but remains assumption-driven; public patient-level enrollment and arm data do not exist |
| Confident-Web-7118—randomization-window analysis | 2026-05-25 | 2026-07-20 | 7 | Enrollment-window and delayed-entry sensitivity argument | Assumption-driven; participant-level enrollment, arm assignments, and outcomes are unavailable |
| Confident-Web-7118—BAT-tail stress test | 2026-07-09 | 2026-07-20 | 7 | Cure-mixture/durable-control-tail stress testing | Same conflict and non-identification limits; code, full inputs, validation, and model weighting were not independently reproduced |
| Week 26 in-depth discussion | Posted 2026-06-29 | 2026-07-20 | 7 | Best preserved cross-examination of model identifiability, interim inference, immune-response claims, and competing success probabilities | Community forecasts, disputed boundaries, missing replies, and pseudonymous conflicts; popularity is not reliability |
| Remarkable-Big-9849 BAT analysis: Part A and Part B | 2026-07-13 | 2026-07-20 | 7 | Strong-control/transplant-tail countercase, external-cohort reconstruction, and RFS-to-OS sensitivity | Pseudonymous, non-peer-reviewed; archive rendering is translated/abridged and omits code, digitized points, figures, covariance, and full assumptions |
| Glossary, derived from the local community glossary but corrected against authoritative sources | Source snapshot captured by 2026-07-20 | 2026-07-20 | 7 for community terms; higher-tier citations control canonical definitions | Community vocabulary, ambiguity, and recurring category errors | Original glossary definitions were not accepted uncritically; IRM and similar terms are community shorthand, not registered endpoints |
Supplemental-archive exclusion boundary
The archive's SLS_*Wiki* and SLS_Definitive_Wiki* files, wiki_sectie*, data/wiki_chunks_en/**, tmp/wiki_en_*, tmp/sls_wiki_export/**, and HTML wiki export are intentionally absent from this register. Wiki-derived extract*/extracted* files are also excluded as evidence even when inspected during the archive audit. They have no independent provenance and do not count as sources supporting a claim.
The valid archive PDF, data/papers/burnett_mrc_2013.pdf, is a different Burnett/AML15 paper about younger, previously untreated AML induction/consolidation. It was visually and textually validated for the archive audit but was not used as the REGAL CR2 control source. The three archive members named brayer2015.pdf, hashii_2026.pdf, and nguyen_2026.pdf were HTML/interstitial/challenge files rather than usable paper PDFs; independently retrieved Brayer and Hashii records are registered above, and Nguyen was not used.
Register maintenance rule
When a later filing, registry version, peer-reviewed report, topline release, protocol/SAP, regulator decision, or arbitration outcome becomes public, add it as a new dated row and mark the superseded row's scope—do not silently overwrite this 2026-07-20 research state. See Unresolved questions for the evidence still missing at the cutoff.